Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, Parinyanitikul N, Supavavej A, Dechaphunkul A, Sunpaweravong P, Neesanun S, Akewanlop C, Dejthevaporn T; TSCO Breast Oncology Group. Dajsakdipon T, et al. Among authors: susiriwatananont t. BMC Cancer. 2024 Aug 16;24(1):1018. doi: 10.1186/s12885-024-12765-x. BMC Cancer. 2024. PMID: 39152401 Free PMC article.
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.
Wanchaijiraboon P, Sainamthip P, Teeyapun N, Luangdilok S, Poovorawan Y, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Susiriwatananont T, Zungsontiporn N, Pakvisal N. Wanchaijiraboon P, et al. Among authors: susiriwatananont t. Vaccines (Basel). 2023 Feb 3;11(2):356. doi: 10.3390/vaccines11020356. Vaccines (Basel). 2023. PMID: 36851234 Free PMC article.
Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment.
Wanchaijiraboon P, Teeyapun N, Pakvisal N, Sainamthip P, Susiriwatananont T, Zungsontiporn N, Suntronwong N, Vichaiwattana P, Klinsawat W, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Poovorawan Y, Luangdilok S. Wanchaijiraboon P, et al. Among authors: susiriwatananont t. Vaccines (Basel). 2022 Oct 5;10(10):1662. doi: 10.3390/vaccines10101662. Vaccines (Basel). 2022. PMID: 36298528 Free PMC article.
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.
Luangdilok S, Wanchaijiraboon P, Pakvisal N, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Sainamthip P, Suntronwong N, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Teeyapun N, Tanasanvimon S. Luangdilok S, et al. Among authors: susiriwatananont t. Vaccines (Basel). 2022 Sep 26;10(10):1613. doi: 10.3390/vaccines10101613. Vaccines (Basel). 2022. PMID: 36298478 Free PMC article.
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.
Pakvisal N, Sainamthip P, Teeyapun N, Luangdilok S, Wanlapakorn N, Yorsaeng R, Poovorawan Y, Pakvisal P, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Tanasanvimon S, Wanchaijiraboon P. Pakvisal N, et al. Among authors: susiriwatananont t. Hum Vaccin Immunother. 2022 Nov 30;18(6):2094149. doi: 10.1080/21645515.2022.2094149. Epub 2022 Jul 1. Hum Vaccin Immunother. 2022. PMID: 35776836 Free PMC article.